NCT06385990View on ClinicalTrials.gov

Utidelone (UTD1) Plus Capecitabine in Non-pCR TNBC After Neoadjuvant Therapy

PHASE2RecruitingINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

March 29, 2024

Primary Completion Date

March 29, 2025

Study Completion Date

March 29, 2027

Conditions
Triple Negative Breast Neoplasms
Interventions
DRUG

UTD1

UTD1: 30mg / m², once a day on days 1-5; capecitabine: 1000mg / m², days 1-14, oral, twice / day; 21 days a treatment cycle of 6-8 cycles.

Trial Locations (1)

410083

RECRUITING

Quchang Ouyang, Changsha

All Listed Sponsors
lead

Hunan Cancer Hospital

OTHER